WaveMan · Company
ISCO · International Stem Cell Corp
> Search tickers & screens ⌘K
LIVE
← All companies

ISCO International Stem Cell (ISCO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001355790
Quote by TradingView
Form 144 · 1
Insider net, 180 days
-$10.5K
Buys minus sells, Form 4 codes P and S
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Revenue growth
+0.2%
XBRL, annual
Net margin
-4.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$9.5M
four quarters, 2025-07-01 to 2026-06-30
History
FY Dec 2025$9.1M
FY Dec 2024$9.1M
FY Dec 2023$7.8M
FY Dec 2022$8.2M
FY Dec 2021$7.2M
Jun 2026$2.7M
Mar 2026$2.3M
Dec 2025$2.2M
Sep 2025$2.4M
Jun 2025$2.4M
Mar 2025$2.1M
Dec 2024$2.4M
Sep 2024$2.2M
At each fiscal year end
Single quarter
Net margin, TTM
-6.1%
net income over revenue, 2025-07-01 to 2026-06-30
History
FY Dec 2025-4.6%
FY Dec 2024-2.3%
FY Dec 2023-1.7%
FY Dec 2022-4.0%
FY Dec 2021-12.5%
Jun 2026-2.7%
Mar 2026-9.5%
Dec 2025-16.1%
Sep 2025+2.4%
Jun 2025+5.3%
Mar 2025-12.0%
Dec 2024+0.4%
Sep 2024-5.7%
At each fiscal year end
Single quarter
Free cash flow, TTM
$333.0K
operating cash flow minus capex, 2025-07-01 to 2026-06-30
History
FY Dec 2025-$35.0K
FY Dec 2024-$153.0K
FY Dec 2023$849.0K
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026$160.0K
Mar 2026$98.0K
Dec 2025$29.0K
Sep 2025$46.0K
Jun 2025-$332.0K
Mar 2025$222.0K
Dec 2024-$75.0K
Sep 2024$220.0K
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-11.0%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-8.4%
FY Dec 2024-4.0%
FY Dec 2023-2.5%
FY Dec 2022-6.6%
FY Dec 2021-17.6%
Jun 2026-11.0%
Mar 2026-7.1%
Dec 2025-8.4%
Sep 2025-1.1%
Jun 2025-4.3%
Mar 2025-4.6%
Dec 2024-4.0%
Sep 2024-12.5%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-130.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
History
FY Dec 2025-73.7%
FY Dec 2024-13.0%
FY Dec 2023-125.3%
FY Dec 2022-31.5%
FY Dec 2021-85.9%
Jun 2026-130.6%
Mar 2026-80.7%
Dec 2025-73.7%
Sep 2025+17.8%
Jun 2025-14.8%
Mar 2025-22.9%
Dec 2024-13.0%
Sep 2024-76.4%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+14.6%
TTM free cash flow over market value at close 2026-10-09
History
FY Dec 2025-3.1%
FY Dec 2024-23.9%
FY Dec 2023+176.8%
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026+21.9%
Mar 2026-11.7%
Dec 2025-3.1%
Sep 2025-13.4%
Jun 2025+2.7%
Mar 2025+28.1%
Dec 2024-23.9%
Sep 2024+17.3%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

ISCO Stock Sonar score 4/7 axes

Find similar shapesCompare

ISCO ranks highest on risk and compliance (99th percentile) and growth (47th), and lowest on insider conviction (30th), among Pharma & Biotech peers.

Profitability
46
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-11.0% · 73 pct, sector of 693
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-130.6% · 19 pct, sector of 578
Growth
47
Inputs
  • Revenue growth, YoY+0.2% · 47 pct, sector of 506
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
30
Inputs
  • Net open-market buying, 180d-$10K · 59 pct, sector of 442
  • Insider buyers, 180d0 · 0 pct, sector of 449
Risk and compliance
99
Inputs
  • Short interest, % of float+0.0% · 100 pct, sector of 814
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+0.6% · 99 pct, sector of 512
3 not measured: Financial health, Institutional and government, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

What the filings say about ISCO

In the 180 days to 2026-10-12, International Stem Cell insiders were net sellers of ISCO, a net $10.5K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-12, covering $11.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-12, dated the day the filing was made public.

ISCO filings FAQ

Are International Stem Cell insiders buying or selling ISCO?

In the 180 days to 2026-10-12, International Stem Cell insiders were net sellers, a net $10.5K across purchases and sales reported on Form 4, by 1 seller.

Are there planned insider sales of ISCO?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-12, covering $11.8K of stock; the latest, by MAIER PAUL V, was filed 2026-09-11.

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$10.5K over 180 days
-$10.5K over 90 days
more than 61% of Pharma & Biotech
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
+0.2% year over year
below 53% of Pharma & Biotech
Margin
-4.6% net margin
more than 69% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
the lowest in Pharma & Biotech
What changed in the last 30 days
Sep 15Director MAIER PAUL V sold $10.5K on the open market (Sep 11)

Watch ISCO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+103.6%12M
-14%+79%+171%+264%2025-102025-122026-022026-042026-062026-082026-10 2026-09-11 · MAIER PAUL V sold $10.5K2026-09-11 · MAIER PAUL V filed to sell $11.8K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $10.5K sold by insiders over 180 days, $11.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

International Stem Cell insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, International Stem Cell CORP insiders sold a net $10.5K of stock across 1 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value
MAIER PAUL V
Director
SELL
2026-09-11
32,802
$10.5K
Context
  • First open-market trade here by this insider on our record.
  • No other insider sold within 30 days.
Insider activity: Director MAIER PAUL V sold about $10.5K of ISCO on the open market on Sep 11, 2026, the largest insider sale at the company on our record.
1 transaction on record · a thin record, read with care
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns ISCO: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in ISCO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ISCO planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
MAIER PAUL V
Filed 2026-09-11
$11.8K
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$88.5K
$136.5K
$370.0K
+75%
n/a
2024
$66.5K
$142.6K
$260.0K
+33%
n/a
2023
$112.9K
$81.6K
$377.2K
-67%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$9.1M$9.1M$7.8M$8.2M
Operating income$-267.0K$-68.0K$-663.0K$-183.0K
Net income$-418.0K$-209.0K$-131.0K$-331.0K
EPS (diluted)-0.05-0.03-0.02-0.04
Operating cash flow$8.0K$13.0K$929.0K$332.0K
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies